e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
Featuring Clinical, Scientific, Tech, AI and Venture Experts
https://worldmedicalinnovation.org/
2020 WMIF | Welcome
34 views1 hour ago2020 WMIF | Disruptive Dozen #1
122 views1 day ago2020 WMIF | Salute to Our Caregivers
12 views1 day ago2021 World Medical Innovation Forum | Gene and Cell Therapy
564 views1 day ago
2020 WMIF | Disruptive Dozen #4
57 views2 days ago
SOURCE
https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg
THIS IS THE EVENT I COVERED on 5/11/2020 BY INVITATION AS MEDIA for Mass General Brigham
From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>
Date: Tuesday, May 12, 2020 at 6:48 AM
To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>
Subject: REGISTRANT RECAP | World Medical Innovation Forum
Dear World Forum Attendee,
On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators. As promised, we wanted to also share visual Forum session summaries. You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning
We hope you will join us for the 2021 Forum!
Thanks again, Chris
Mass General Brigham (formerly Partners Healthcare) is pleased to invite media to attend the World Medical Innovation Forum (WMIF) virtual event on Monday, May 11. Our day-long interactive web event features expert discussions of COVID-related infectious disease innovation and the pandemic’s impact on transforming medicine, plus insights on how care may be radically transformed post-COVID. The agenda features nearly 70 executive speakers from the healthcare industry, venture, start-ups, consumer health and the front lines of COVID care, including many of our Harvard Medical School-affiliated researchers and clinicians. The event replaces our annual in-person conference, which we plan to resume in 2021.
Aviva Lev-Ari, PhD, RN, Editor-in Chief, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston will cover the event in Real Time as MEDIA for our Coronavirus Portal
CORONAVIRUS, SARS-CoV-2 PORTAL @LPBI
http://lnkd.in/ePwTDxm
Launched on 3/14/2020
8:15 – 8:25 AM
Opening Remarks
Dr. Klibanski will welcome participants to the 2020 World Medical Innovation Forum, a global — and this year, virtual — gathering of more than 5,000 senior health care leaders. This annual event was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together to improve patient lives. No collaborative endeavor is more pressing than responding to the COVID-19 pandemic.
Introduction:
Scott Sperling, Co-President, Thomas H. Lee Partners; Chairman of the Board of Directors, Mass General Brigham
- Introducing Anne Klibanski – Leadership at its best for breakthroughs in the entire system when return to normalcy
Anne Klibanski, MD, President & CEO, Mass General Brigham
- Collaborative innovation between Industry and Hospitals and Government
- Expediting innovations: Prophylactic, Diagnostics, research and care delivery
- COVID caregivers contribution to this battle, patient experience and outcome
8:25 – 8:50 AM
Care in the Next 18 Months – Routine, Elective, Remote
Hospital chief executives reflect on how health care will evolve over the next 18 months in the face of COVID-19. What will routine health care look like? What about elective surgeries and other interventions? And will care-at-a-distance continue to be an essential component? Simply put, how will we provide manage, and pay for health care in a world forever changed by COVID-19?
Moderator:
Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS
John Fernandez, President, Mass Eye and Ear and Mass General Brigham Ambulatory Care
- Out patients decrease in volume now social distancing enabled by using parking lot as waiting rooms
- Pre visit and post visit websites will become places of touch – patients accessing via website
Elizabeth Nabel, MD, President, Brigham Health; Professor of Medicine, HMS
- Support to frontline care
- Old normal will not be the new normal
- Telehealth and digital health, work force, healthcare experience, improve access
- lower medical expense
- Patients were afraid
- deferred cancer operation and treatment
- Cath Lab less 50% occupied
- Hospitals are safe and patients must come back for procedures
- COVID-19 only 20% of all patients
- ICU and OR Scheduling rethink procedure digital care delivers procedures
- deploy workforce work across repurposed units hybrids, talent acquisition new strategy
- COVID-19 will have distinct areas
- BWH – Patient-Nurse-Doctor relations in healing Healthcare team became the Family of the Patients
Peter Slavin, MD, President, MGH; Professor, Health Care Policy, HMS
- Reemerging more complicated
- In patients and Out patient realigned with care for COVID-19
- Telemedicine 85% of outpatients visits at MGH
- virtual care will dominate the future of care
- disadvantaged populations suffered more in the pandemic Communities in Chelsea and Revere household received kits social determinants of illness
8:50 – 9:15 AM
COVID-19: Technology Solutions Now and in the Future
Experts leading large teams at the epicenter of the coronavirus outbreak discuss how technology is shaping the pandemic response today and in the coming years. What technology categories are most important? What tools are healthcare organizations, biopharmaceutical companies, and other organizations leveraging to battle this crisis? How will those tools evolve? And, importantly, how can technology inform the medical response to future pandemics? What were the biggest technology surprises in the current response?
Moderator:
Alice Park, Senior Writer, Time
Stephane Bancel, CEO, Moderna
- mRNA synthetic RNA of Spike protein injected to stir immune response
- Phase II working with FDA starting Phase III early Summer
- 15 mcg dose available in 2020
- using own capital to invest to scale up manufacturing no help from Gov’t Grant for clinical trial not for manufacturing
Paul Biddinger, MD, Medical Director for Emergency Preparedness, MGH; Associate Professor of Emergency Medicine, HMS
- Sharing information across the system aggregate data technologies
- ML as Guidance in resource coordination
David Kaufman, MD, PhD, Head of Translational Development, Bill & Melinda Gates Medical Research Institute
- drug development, clinical operations remote monitoring
- repurpose compounds usinf libraries
- scalability and Global vaccine cheap and available globally
- complexity is in coordinations – toolset biology tool RNA mapping viral screening primaru cells and organoids
- Outcomes: Aging and co-morbidities
- Discovery effort using tools infrastructure maintained between pandemics
Rochelle Walensky, MD, Chief, Infectious Disease, Steve and Deborah Gorlin MGH Research Scholar, MGH; Professor of Medicine, HMS
- shared photos important for Public health, using iPhone distribution Demedicalize Testic – not only at clinics but at many placed contact tracing and diagnosis in 24 hours – iPhone is invaluable GPS capability – privacy issues
- detect patients with high risk and existing infection monitoring
- Public Health – Thermometer given to Patients – data collected centrally any spike and pulse oximeter given to home – remote
- Anxiety in opening the economy requires a bit of giving up on privacy
- TeleHealth and monitoring remotely
- Pharmacy and workplace as points to start Testing vs Order and a nurse call
9:15 – 9:40 AM
Digital Health Becomes a Pillar: Tools, Payment, Data
Deployed in the crucible of the coronavirus pandemic, digital health has now become an essential pillar in the delivery of care. Why is that significant? How and why did it happen? What are the essential tools and components? How is the electronic health record and other health data contributing to this digital movement?
Are there novel use cases for telehealth that arose during the first phase of the COVID-19 pandemic? How can digital technologies help enable a full return to work. Thinking ahead to the fall and a possible second wave, are there things we should be doing today to ensure this technology to better detect and profile a resurgence and enhance the patient benefit.
Moderator:
David Louis, MD, Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, HMS
- DIgitsl technologies – boostong and innovating
- upscale activity
- risk of upscaling on Providers
- Adaptations of innovation
Alistair Erskine, MD, Chief Digital Health Officer, Mass General Brigham
Adam Landman, MD, VP, Chief Information and Digital Innovation Officer, BH; Associate Professor of Emergency Medicine, HMS
- COVID-19 call center across Partners, Chat bots automated screening tools, Microsoft assisted 60,000 users of chat bots triaging by screening calls of the Hotline
- TeleHealth transformation may be lost due to reimbursement which may not be reimburse after the emergency is over Insurers to incentivize use of of TeleHealth
- In person care: Redesign and how to provide In care for the staff and for the Patients
Brooke LeVasseur, CEO, AristaMD
- Access problem due to care shortage of specialty care
- technology better allocate resources
- Industry and Hospital Institutions populations they serve
- innovations needs a sustainable economic model for reimbursement
- Inequity issues How Telehealth can benefit all of Society, potential for future solutions
Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Vice President, Virtual Care/Digital Health, Mass General Brigham; Professor, Neurology, HMS
- Surge capabilities
- generate insight
- Research and Innovation needs embedding in the enterprise
- technical gap in maintenance
- supply chain disrupted
9:40 – 9:45 AM
BREAK
9:45 – 10:05 AM
FIRESIDE CHAT
Bayer Pharma Reflections on Innovation: Creating, Collaborating, and Accelerating Discovery During and After a Pandemic
Dr. Moeller will reflect on how Bayer is weathering the organizational challenges posed by the COVID-19 pandemic. How does a global pharmaceutical company continue to drive drug development when its labs are shut down? What are the critical elements needed to keep the engines of innovation firing even in the face of a global public health crisis? How does a global r&d enterprise plan for an uncertain fall 2020 given a potential return of the virus.
Introduction:
John Fish, CEO, Suffolk; Chairman of Board Trustees, Brigham Health
- COPD
Moderator:
Janet Wu, Bloomberg
Joerg Moeller, MD, PhD, Head of Research & Development, Pharmaceuticals Division, Bayer AG
- led team of 9 products
- Unprecedented is COVID-19: effect on work, travel, life
- Anti-Malaria vs COVID-19: In China testing early chloroquine approved for RA and anti Malaria Government in China experimental and Bayer supports Clinical Trials by Bill & Melinda Foundation
- In 8 weeks most Scientist work from home – amazed what was accomplished by 80% of Bayer working from home
- production is kept ongoing anti-infective for Pneumonia
- focus on most critical and keep experiment critical and push out studies run Globally – No pre-maturely study was interrupted completely
- Great collaboration Flexibility with regulatory agencies in Europe and with FDA – levels not seen before
- R&D in Pharma – when out different point than when we started: Opportunities- Compound libraries OPEN after the COVID Pandemic, speed of decision making, team spirit outstanding – levels not seen before
- Partnerships: Bayer testing machines and ventilators shared, accelerate mechanisms for new drug development
- evidence for repurposing drugs: Chloroquine
- Solidarity – everyone are in it TOGETHER, keep that after the Pandemic is over – levels not seen before
10:05 – 10:30 AM
The Patient Experience During the Pandemic
The coronavirus outbreak is not only testing health care staff and resources, it is also having an overwhelming impact on patients. This panel will focus on the approach and technologies providers are using to address the patient experience along the continuum of care.
Moderator:
Thomas Sequist, MD, Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, HMS
Anjali Kataria, CEO, Mytonomy
- Video overcome illiteracy and provide personal engagement without the negative
- Home health will be the shift – a human component will not go away – sensor technology in car, bathroom
- COVID-19 accelerated user adoption of Telehealth
- Digital technologies as an equailizer Hispanic patients consumed for information with the new technologies
Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, BH; Harriet Ryan Albee Professor of Medicine, HMS
- conserve PPE impacted Physicians ability to see Patients, Nurses meet patients vs Physicians that delivered care remotely – laying on hands was missing in the care
- Masks will not come off but in a while, can’t allow the infection to surge and curtail hospitals from functioning, use mask for the foreseable future
Peter Lee, PhD, Corporate Vice President, Microsoft Research and Incubation
- Interactive Chat bots 1 out of 500 hospitals around the Globe adopted the Chat Bot for Patient Intake
- Scaling telemetry with feedback loop
- iPad at bedside, platform orchestration, new workflows for COVID-19 patients in the backend guiding Patients in the Process was new infrastructure was in the front line
- preparing for a game change in Medicine: Patients demanding new experience
- Historical context for physicians contribution to care and bridge the digital divide
Jag Singh, MD, PhD, Cardiologist & Founding Director, Resynchronization and Advanced Cardiac Therapeutics Program, MGH; Professor of Medicine, HMS
- Isolation is unbearable
- Predictive analytics
- no going back to before Pandemic
- COVID-19 only severe go to hospital
- Human contact enhanced interaction with families and Docs
10:30 – 10:55 AM
The Role of AI and Big Data in Fighting COVID-19 and the Next Global Crisis – Successes and Aspirations
AI is a key weapon used to fight COVID-19. What are the biggest successes so far? Which applications show the most promise for the future? Can it help a return to work? Can AI help predict and even prevent the next global health care crisis?
Moderator:
Alice Park, Senior Writer, Time
Mike Devoy, MD, EVP, Medical Affairs & Pharmacovigilance and CMO, Bayer AG
- AI allows speeding up Genome of Spike Proteins sequencing
- Partnership with Academia help focus effort
- openness and willingness to collaborate and take risk in Therapeutics
Karen DeSalvo, MD, Chief Health Officer, Google Health
- Partnership with Apple on Contact Tracing System – BLE – only for Health applications
- Public Health as driver as consumer Privacy preserving
- Individual level data collection for AI applications, privacy giving up for public good
- Trust component – in sharing data
Keith Dreyer, DO, PhD, Chief Data Science Officer, Mass General Brigham; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
- COVID allowed data on contact tracing
- AI in image capturing for Public health – target Imaging use data to be equivalent to Human Testing at Home va in ER 1 in 10, 000 vs all populations
- Data to AI application SW providers are stewards Open source , no conflict of interest and no discussion on profits
- Each country will have own lessens
10:55 – 11:20 AM
Designing for Infection Prevention: Innovation and Investment in Personal Protective Equipment and Facility Design
As with many pathogens, prevention is the best defense against SARS-CoV2, the virus that causes COVID-19. Panelists will discuss the insights, design strategies, technologies, and practices that are emerging to guard against infection and how those innovations are being applied to protect health care providers and their patients.
Based on what was learned during the spring of 2020, are there specific changes that will lessen morbidity and mortality in a potential a second wave?
Moderator:
Erica Shenoy, MD, PhD, Associate Chief, Infection Control Unit, MGH; Assistant Professor, HMS
Shelly Anderson, SVP, Strategic Initiatives and Partnerships, & Chief Strategy Officer, BH
- How to establish the New normal
- Surveillence for new sources of infection
- Operations under uncertainty
- learned to be effective with data monitoring, training, facility adaptation to new roles
- Investments in new materials to stabilize the supply chain: Additional suppliers,
- Extend internal supply work with R&D on alternative materials
Michele Holcomb, PhD, EVP, Strategy and Corporate Development, Cardinal Health
- Optimize toward lower cost vs availability of supply
- Diverting supply chain to manufacturing not in PPE business
Guillermo Tearney, MD, PhD, Remondi Family Endowed MGH Research Institute Chair, Mike and Sue Hazard MGH Research Scholar, MGH; Professor, Pathology, HMS
- 3D Printing innovations for filtration capacity of particles, respirators decontaminated, prevention of patient transmission
- Negative pressure applied on materials as second line of protection beyond PPE
- CPAP to be used
- weaning from Ventilators to CPAP
- Environment to be protected from air born pathogens
Teresa Wilson, Director/Architect, Colliers Project Leaders
- Physical Design of the facility and rooms – use design to minimize Hospital infections principals of location of clean vs dirty functions
- room kept cleaned, how long it takes to clean, where is the sink, hands free, modular construction plug & play design of rooms functions
11:20 – 11:25 AM
BREAK
11:25 – 11:45 AM
FIRESIDE CHAT
Preparing for Fall 2020 and Beyond: Production, Innovation, Optimization
How does a global medical technology and life sciences company respond to the health challenges posed by COVID-19? Mr. Murphy will reflect on how his organization is working to meet the unprecedented demand for life-saving medical equipment for diagnosing, treating, and managing coronavirus patients. How does a large manufacturer make adjustments to FDA regulated products and supply chains in time to help lessen the impact of a second wave of COVID-19 infections.
Introduction:
Jonathan Kraft, President, The Kraft Group; Chair, Mass General Hospital Board of Trustees
- 90 countries around the Globe – collaborative innovations partnership with GE Health – all assets around the World
- Academic with GE Health AI, Diagnostics, data set for ML for Health care
Moderator:
Timothy Ferris, MD, CEO, MGPO; Professor, HMS
Kieran Murphy, CEO, GE Healthcare
- Partnership GE Health & MGH
- COVID-19 Innovations and Customers needs: Ventilators and
- ICU Cloud application with Microsoft to save PPE and Labor, monitor several ICU rooms at once by technology
- Quadruple the production and enter new contracts, crisis exposed weaknesses in supply chain of many products
- Shortage of PPE was not expected, flexibility and trusted relations with GE Health Suppliers
- CT in a BOX – 42 Slices in a container – no exposure to radiation in prefabricated rooms in field hospital requiring no contact with clinicians and rapid response
- Command control center with John Hopkins University
- Manufacturing facilities in China communicate the situation of the business and the customers needs buyers in the Health care industry
- Future for Biotech industry: Modular systems deploy rapidly, test vaccine, SPEED is everything productivity & Speed
- Productivity will increase collaboration and speed like partnership with FORD and MIcrosoft
11:45 AM – 12:10 PM
Big Tech and Digital Health
Tech giants are dedicating their vast resources to aid in the global response to the coronavirus. This panel will highlight how the big data and computational power of major tech companies is being deployed to help contain the current pandemic through new technologies and services, enable return to work, and how it could help prevent future ones.
Moderator:
Natasha Singer, Reporter, New York Times
Amanda Goltz, Principal, Business Development, Alexa Health & Wellness, Amazon
Michael Mina, MD, PhD, Associate Medical Director, Molecular Virology, BH; Assistant Professor, Epidemiology, Immunology and Infectious Diseases, Harvard Chan School
- Limitations on Viral Testing
- Shortage of Swabs for testing
- Tech giant: Amazon, Walmart – global reach in supply chain
- new collaborations formed on super charge
- Antigen test for home administration consumerization of the Testing
- Walmart can be positioned for blood tests
- Not only Physicians can order tests
- Microsoft and Amazon can help in interpretation of the Test using Alexa
Marcus Osborne, VP, Walmart Health, Walmart
Jim Weinstein, MD, SVP, Microsoft
12:10 – 12:35 PM
LUNCH BREAK
12:35 – 12:55PM
FIRESIDE CHAT
Insights on Pandemics and Health Care from the National Security Community
General Alexander, a renowned expert on national security as well as pandemics and health care, will reflect on how AI can help identify and predict future global disease outbreaks and enable fully reopening commerce. He will also discuss what health care systems can learn from the response to COVID-19 to ensure preparedness for the next infectious disease challenge.
Moderator:
Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS
General (Ret) Keith Alexander, Co-CEO, IronNet Cybersecurity
12:55 – 1:20 PM
Calibrating Innovation Opportunity and Urgency: Medical and Social
The social and medical needs of patients are deeply intertwined, yet there are significant gaps in the tools and technologies being developed to help address those needs. These are especially apparent in the non-uniform impact of COVID-19. Harnessing opportunities, particularly for patients whose needs fall into the low medical complexity/high social complexity category — a group often overlooked by health care innovators.
Moderator:
Natasha Singer, Reporter, New York Times
Giles Boland, MD, Chair, Department of Radiology, BH; Philip H. Cook Professor of Radiology, HMS
- Boston Hope: 1400 patients were treated at Boston Convention Center, 700 COVID -19 patients and 700 post acute after release from ICUs
- Policy makers to address social determinants of Health
Amit Phadnis, Chief Digital Officer and GE Company Officer, GE Healthcare
- Crisis will go away the innovations will stay and develop
- Population Health to benefit from iPhone in Africa and in India mapping hotspots in populations
- Multi channels TV, Phones and other devices – social disparities – no app to address social inequality
Krishna Yeshwant, MD, General Partner, GV; Instructor in Medicine, BH
- communities most affected by social determinants of Health like in Chelsea in MA, a hotspot for COVID-19
- Google Ventures – social issues are most complex invest in underprivileged
1:20 – 1:45 PM
FDA Role in Managing Crisis and Anticipating the Next
The FDA and other regulatory bodies have played a key role in managing the coronavirus pandemic. How will the agency’s priorities shift in the coming months as community transmission (ideally) slows? What is the FDA’s role in return to work? What is the FDA doing to anticipate future health crises? How will these drive new tools and effect that rate of innovation?
Moderator:
Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS
Amy Abernethy, MD, PhD, Principal Deputy Commissioner & Acting CIO, FDA
- Future – common tools, more efficient studies study protocols and study design evaluation
- Learned what need to be put in place to move fast learn what is not in place
- post pandemic regulatories lessons for being ready for the next one
Lindsey Baden, MD, Director, Clinical Research, Division of Infectious Diseases, BH; Associate Professor, HMS
- Identify diagnostics for clinical definition of a virus unknown
- treatment to be developed
- Sick patients in need for treatment, researchers and clinicians need the best available FDA and the hospitals are flexible in responding
- Spread globally like a respiratory virus
- IRB – fast than ever before FDA and Pharma, DSMB – speed
1:45– 2:05 PM
FIRESIDE CHAT
Keeping Priority on the Biggest Diseases
Biogen CEO Michel Vounatsos will discuss how Biogen is tackling some of society’s most devastating neurological and neurodegenerative disorders, and share his perspective on the impact the global COVID-19 pandemic is having on the biopharmaceutical industry.
Moderator:
Jean-François Formela, MD, Partner, Atlas Venture
- Testing programs – lack of government cooordination
Michel Vounatsos, CEO, Biogen
- Venture community supportive
- to be on the safe side
- employees tested every evenings to prevent rebound of the pandemic
- Pandemic is acceleration progress that was only dreamt about
- Opportunities in technologies new drugs,
- Biogen will lead the new model
- ALS – rare genetic expression Phase I encouraging
- Neuro-immunology – MS phase III Parkinson drug
- Lessons from COVID-19: Delay in clinical trials because Patients are fearing Hospital admission – Stroke patient did not go to Hospital
- Biogen is joining the fight against COVID
- Neuroimmunology is the strength – remain focus
2:05 – 2:30 PM
Building the Plane While Flying: The Experience of Real-Time Innovation from the Front Line
The COVID-19 crisis has required continuous, real time innovation, impacting the way care is delivered on the front lines and across care continuum. This panel will present the perspective, innovations and experiences of care givers interacting directly with patients across the continuum of care – acute, post-acute, rehab and home care.
Moderator:
Ann Prestipino, SVP; Incident Commander, MGH; Teaching Associate, HMS
- coming out of crisis
- the New normal will be diferent
Theresa Gallivan, RN, Associate Chief Nurse, MGH
- Ambulatory procedures
- 700 nurses were deployed
- 164 ICU beds increase of 90%
- Health care demand will change in the future
- focussed problem alarms from ventilators were not coordinated till biomed engineers arrives to device a solution
Karen Reilly, DNP, RN, Associate Chief Nursing Officer, Critical Care, Cardiovascular and Surgical Services, BH
- Collaborate and move forward
- Interdisciplinary team: Physical therapy help quickly
- tech to communicate with families
- Ready – I wish I had information to stay ahead of the curve
- New normal ability to expand and contract
Ross Zafonte, DO, SVP, Research Education and Medical Affairs, SRN; Earle P. and Ida S. Charlton Professor of Physical Medicine and Rehabilitation, HMS
- Rehabilitation in Cambridge Spaulding Brighton
- Off loading to rehab from other units
- Flexibility MGH Brigham – learn to be a new organization
- Hotspots optimal mapping
- Right person at right challenge
- Stay ready for catastrophies
- Telecare and Tele rehabilitation – greater benefit on TeleHealth or not who will not benefit from Rehab
2:30 – 2:55 PM
CEO Roundtable: Will the Innovation Model Remain as It Was
As we envision a post-COVID-19 world, how will the model for biomedical innovation change? What lessons have been learned? Was this pandemic a once-in-a-lifetime event or should organizations begin to weave pandemic planning into their business and operations strategies? Panelists will discuss these and other related questions.
Moderator:
Janet Wu, Bloomberg
Mike Mahoney, CEO, Boston Scientific
- China 6% of Sales
- Employees – 148 Counties
- support hospitals – 57% of volume
- Resilience for liquidity Variable cost needed be removes partially
- How will the company come out stronger
- Innovations by business model innovations – Remote physicians in Japan by European experts in OR
- Next week 10% of Product management and Quality are priority to come back
- working remotely works very well except for R&S who needs Labs
Bernd Montag, PhD, CEO, Siemens Healthineers
- Keep present business and the emerging needs for technologies
- Serology Test
- Antibody Test genomic testing
- Company is Global but Health care is local
2:55 – 3:05 PM
BREAK
3:05 – 3:30 PM
Emergency and Urgent Care: How COVID-19 Vulnerabilities and Solutions Will Change the Model
How are the roles of emergency medicine and urgent care changing in light of the COVID-19 pandemic? Panelists will discuss this topic as well as how current and anticipated new technologies can aid in the delivery of community, urgent, and emergency care now and in the future.
Given a false negative at the point of care has consequences well beyond the patient being treated, does this change what can be offered in the various patient care settings?
Moderator:
Ron Walls, MD, EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, HMS
Troyen Brennan, MD, EVP and CMO, CVS Health
- Labs – Quest Diagnostics
- Point of care – Tests will move to Home will replace Labs
- Pandemic heated hard people of color and comorbidities
David Brown, MD, Chair, Department of Emergency Medicine, MGH; MGH Trustees Professor of Emergency Medicine, HMS
- Tele Urgent care
- EMS Providers using TeleHealth
- Scaled up capability needed administered by Governmental agency
- new surges of some disease after Re-opening
- Sensitivity of test for ill patient
- Demand for Urgent Care will decline higher acuity will increase
Julie Lankiewicz, Head, Clinical Affairs & Health Economics Outcomes Research, Bose Health
- Management of care with VRE other microbial agents
- Vulnerable populations EKG between patients no more
- mitigation of care – Brand new prescriptions for Anxiety and burnout
- Digital solution to replace medications – audio content to avoid pharmacology by other methods of relaxation
- Herd immunity – Digital transformation
Michael VanRooyen, MD, Chairman, Department of Emergency Medicine, BH; Director, Humanitarian Initiative, Harvard University; Professor, HMS
- Separate Patients from Providers
- Infection threat – Intubation – Tent for airsolize – trap air in the hood
- manage Emergence Health OUT side of EM at Hospital
- Rapid testing will continue to be central in Emergency Care
3:30 – 3:55 PM
Accelerating Diagnostics – Maintaining the Priority: Lab, Home and Digital
COVID-19 diagnostics, a linchpin in controlling viral spread — what caused testing in the U.S. to fall so far behind and how can those missteps be prevented in the future? How do the diagnostics industry, and academic medicine, develop the tests that enable group activities including businesses sports, and community? What is the profile of diagnostic tests coming online in the coming months and into next year? What lessons can be learned to guide the global health community in future disease outbreaks? Given the biological complexity, required performance standards, and immense volume is a simple DTC assays possible on a greatly accelerated timeline.
Moderator:
Jeffrey Golden, MD, Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, HMS
James Brink, MD, Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS
- social determinant of care – communities not able to social distance, multiple languages
- Radiology: Rapid evolution of pandemic
- MGB – Standardizations
John Iafrate, MD, PhD, Vice Chair, Academic Affairs, MGH; Professor, Pathology, HMS
- Ability for Rapid testing was not in existence in the US
- CDC Test deployed
- BD and Roche diagnostics will
- recipients and donors of antibodies
Celine Roger-Dalbert, VP Diagnostic Assays R&D – Integrated Diagnostic Solutions, BD Life Sciences
- Telemedicine collection of samples outside the hospital
- Testing if a patient had – serology – antibody – past exposure after day 14
- Testing if a patient has – PCR after 10 days the virus is not infectious but it is present
- antigen detection testing
- molecular test
Matt Sause, President and CEO, Roche Diagnostics Corporation
- Serology – more people become infected
- active infection
- Partnership between FDA and the manufactures
- In the US scaling – infrastructure in place is a must
3:55 – 4:15 PM
FIRESIDE CHAT
Return to Work: Understanding the Technologies and Strategies
Diagnostic testing is a linchpin of the worldwide response to the coronavirus. How does a global leader pivot to develop molecular diagnostics for a novel global pathogen? How does it scale, including managing international supply chains, to provide unprecedented levels of products and services. What are the expectations for return to work and a possible disease spike in fall 2020 or beyond. How will the diagnostics industry be permanently changed.
Moderator:
Peter Markell, EVP, Finance and Administration, CFO & Treasurer, Mass General Brigham
Marc Casper, Chairman, President and CEO, Thermo Fisher Scientific
- Re-opening the economy requires Testing for certification of health
- Testing bringing confidence
- PCR – have or have not viral proteins: 5Millions a week, June 10 million tests
- antibody testing will also become available in massive scale
- Supply chain, more preparedness, robustness of the supply chain
- Buying supply in China vs US based
- stockpiling by governments not only at the Hospital level vs JIT shocks to the system
- Work from home – productivity is good, work from home not ideal environment
- Transportation and elevators – social distancing – impossible
- Global change enormous Telemedicine ramp up Academic center Telemedicine will prevail
- more resilient Health care system dialogue and communications across countries technology will play a role it will improve Health care every where
4:15 – 4:40 PM
Digital Therapeutics: Current and Future Opportunities
Digital therapeutics (DTx) represents an emerging class of therapies that is poised for significant growth. Yet already, these software-driven, evidence-based tools for the prevention, management, and/or treatment of disease are already changing patients’ lives. This panel will address how existing DTx are having an early impact — in the COVID-19 pandemic and — and where current development efforts are headed in the coming years especially if there is a aggressive return of the virus in the fall 2020 or later.
Moderator:
Hadine Joffe, MD, Vice Chair for Research, Department of Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, HMS
Priya Abani, CEO, AliveCor
- Medical grade EKG devices
- Telemedicine on the rise
Julia Hu, CEO, Lark Health
- AI 24×7 counseling data streaming in data
- TeleHealth
- VirtualHealth Provider – working hard to scale
- Patients @Home work at their schedule 9PM – midnight text messaging
- 70% in employment reported stress experienced by employees
Dawn Sugarman, PhD, Assistant Psychologist, Division of Alcohol, Drugs, and Addiction, McLean; Assistant Professor, Psychiatry, HMS
- Opioid & substance abuse
- Treatment gap for women – gender specific Programs online gender specific treatment
4:40 – 5:05 PM
Investing During and After the Coronavirus Crisis
The investment environment in life sciences and health care overall was at record levels for most of the last decade. What will this environment look like in the wake of the COVID-19 pandemic – especially over the near to mid-term? Will investor priorities and enthusiasm shift? What is the investor role in developing new coronavisurs tests, vaccines, and therapeutics?
Moderator:
Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham
Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures
- Can you close a deal with out meeting management team
- Known funds will prevail vs new funds Parma adjacencies vs medical devices
- Telehealth is of interest GI, Cardiovascular
- Mental health with TeleHealth
Phillip Gross, Managing Director, Adage Capital Management
- Clinical Trial issues
- Inflating value of Biotech because therapeutic related to COVID gives a boost
- 90 programs in clinical trials on Vaccine
Christopher Viehbacher, Managing Partner, Gurnet Point Capital
- Health care was great investment because prople will get sick.
- deal making switch to zoom meeting, no site visit, banking is adapting
- relationship with people you do not know will be very hard
- early stage if the cloud exist
- Medical profession: Healthcare system is hurting revenue loss new technologies
- clinical trials will be changing like for COVID
- Sharing data will accelerate science
5:05 – 5:10 PM
Closing Remarks
Mass General Brigham (formerly Partners Healthcare) is pleased to invite media to attend the World Medical Innovation Forum (WMIF) virtual event on Monday, May 11. Our day-long interactive web event features expert discussions of COVID-related infectious disease innovation and the pandemic’s impact on transforming medicine, plus insights on how care may be radically transformed post-COVID. The agenda features nearly 70 executive speakers from the healthcare industry, venture, start-ups, consumer health and the front lines of COVID care, including many of our Harvard Medical School-affiliated researchers and clinicians. The event replaces our annual in-person conference, which we plan to resume in 2021.
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
FrasonKalapurackal
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply